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ABSTRACT
This study analysed the proportions of Acineto-
bacter baumannii isolates resistant to various
antibiotics that were recovered from patients
hospitalised in Greek hospitals between 1996
and 2006. The microbiological data were derived
from the ongoing WHONET Greek System for the
Surveillance of Antibiotic Resistance. There were
increases in the proportions of A. baumannii
isolates resistant to imipenem from patients hos-
pitalised in intensive care units, medical wards and
surgical wards during the study period from 0% to
91%, 8% to 71%, and 5% to 71%, respectively.
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The selective pressure of antimicrobial agents
contributes to the increasing problem of antimi-
crobial resistance. Acinetobacter baumannii is a
pathogen that has rapidly accumulated resistance
mechanisms to most antibiotics [1–6], thus limit-
ing treatment options [7] and resulting in
increased morbidity and mortality. There are
differences in the proportions of resistant strains
isolated from different countries, different hospi-
tals within the same country, or different wards
within the same hospital; however, the trend
towards increasing resistance in this species is
undisputed. The present study analysed the
trends of antimicrobial resistance among A. bau-
mannii isolates from patients hospitalised in
various hospitals in Greece during the period
1996–2006 in order to develop treatment guide-
lines. The microbiological data were derived from
the ongoing WHONET Greek System for the
Surveillance of Antibiotic Resistance.
Identification of A. baumannii and sensitivity
testing were performed by the routine methods
used in the respective participating hospitals,
which included the use of automated systems
such as the Vitek, Wider, Phoenix and Microscan.
Only the first isolate per patient was processed.
Varying numbers of hospitals provided data
concerning isolates and their in-vitro suscepti-
bilities during the 11-year study period. The
grouping of isolates as susceptible, intermedi-
ately-resistant or resistant was based on CLSI
criteria [8]. Isolates considered to have interme-
diate resistance were classified in the resistant
group for the purposes of this analysis. All
hospitals performed internal quality control, and
also participated in the external quality control
programme organised by UK NEQAS.
Table 1 summarises the proportions of A. bau-
mannii isolates obtained from patients hospitalised
in the intensive care units (ICUs) of the participa-
ting Greek hospitals between 1996 and 2006 that
had full or intermediate resistance to seven anti-
microbial agents. There was an increase in the
proportion of isolates with resistance to imipenem
(from 0% in 1996 to 91% in 2006) and to pipera-
cillin–tazobactam (from 84% in 2002 to 98% in
2006), and the proportion of isolates with multi-
drug resistance (resistance to ceftazidime, cipro-
floxacin and amikacin) rose from 73% in 1999 to
86% in 2006. The lowest proportion of resistant
isolates (57%) in 2006 comprised those with
ampicillin–sulbactam resistance, and this figure
was relatively stable throughout the study period.
Table 2 summarises the proportion of A. bau-
mannii isolates from patients hospitalised in
medical and surgical wards of Greek hospitals
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that had full or intermediate resistance during
the study period. The rise in the proportion of
isolates with resistance to various antimicrobial
agents is obvious, and is particularly so in the
case of imipenem resistance (from 8% in 1996 to
71% in 2006), piperacillin–tazobactam resistance
(from 0% in 1996 to 83% in 2006), cefepime
resistance (from 49% in 1997 to 86% in 2006)
and multidrug resistance (from 51% in 2002 to
75% in 2006). Ampicillin–sulbactam was the
most active agent in 2006, with only 49% of
isolates showing resistance. Similar observations
were made for patients in surgical wards. No
significant differences in the antimicrobial resist-
ance rates were observed among the major
tertiary general hospitals that participated in
the data collection.
Data concerning the overall proportion of
A. baumannii isolates among all clinical isolates
from patients receiving care in hospital wards
and ⁄ or ICUs in the participating hospitals were
also analysed. These analyses revealed that the
proportion of A. baumannii isolates ranged during
the 11 years of the study from 2.1% to 4.3% in
medical wards, from 2.7% to 7.1% in surgical
wards, and from 15.3% to 22.6% in ICUs. A. bau-
mannii was the 7th)9th most frequently isolated
microorganism from patients in medical wards
throughout the study period, the 5th)9th from
patients in surgical wards, and the 1st)3rd from
patients in ICUs.
The most noteworthy finding of the present
study was that there had been an increase in the
in-vitro resistance to various antimicrobial agents,
including imipenem, of A. baumannii isolates from
patients hospitalised in Greece. The striking
increase in resistance to carbapenems is of
particular interest, since this class of antimicrobial
agent was, until recently, considered to be among
the most potent against many microorganisms,
including A. baumannii. All isolates obtained from
patients hospitalised in ICUs during 1996 were
susceptible to imipenem. However, the propor-
tion of isolates resistant to this antibiotic increased
throughout the study period, to reach a figure of
91% in 2006. Interestingly, although increased
resistance to carbapenems has also been observed
in Pseudomonas aeruginosa and Klebsiella pneumonia
isolates from Greece during the last 3 years, this
has been associated with the emergence and
spread of strains producing metallo-b-lactamases
of the VIM type [9,10], while the importance of
these enzymes in Acinetobacter seems to be limited
[11]. However, it seems that dissemination of
carbapenemases is responsible, at least in part, for
the emergence of imipenem-resistant A. bauman-
nii clones [12,13].
The development of new antibiotics, active
against resistant isolates of A. baumannii, has
become one of the most challenging targets of
modern medicine [14–16]. The present data sug-
gest that polymyxins should be considered for the
Table 1. Antimicrobial resistance of Acinetobacter baumannii isolates from patients in intensive care units in Greece
Proportion of isolates with full or intermediate resistance
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006a
Ampicillin–sulbactam ND 46 40 ND ND ND 44 65 63 55 57
Piperacillin–tazobactam ND ND ND ND ND ND 84 91 96 96 98
Ceftazidime ND 96 92 93 88 85 88 94 98 95 95
Cefepime ND 81 84 ND ND ND 91 95 97 92 94
Imipenem 0 16 17 ND 10 27 44 66 64 78 91
Amikacin ND 78 82 81 79 82 86 86 86 84 90
Ciprofloxacin 93 88 86 86 90 91 94 97 98 99 98
MDRb ND ND ND 73 68 63 74 79 86 86 86
aData available for the first semester of 2006.
bMultidrug-resistant (resistance to ceftazidime, ciprofloxacin, and amikacin).
ND, no data.
The numbers of isolates tested and the maximum number of hospitals that provided data (in parentheses) per year for the 11 consecutive years of the study (1996–2006) were,
respectively: ampicillin–sulbactam, 0, 294 (16), 610 (23), 0, 0, 0, 282 (9), 560 (7), 662 (10), 1009 (17), 331 (13); piperacillin–tazobactam, 0, 0, 0, 0, 0, 0, 926 (21), 1633 (16), 1981 (19),
2291 (27), 1123 (22); ceftazidime, 0, 346 (16), 668 (23), 815 (12), 871 (17), 1123 (19), 1652 (25), 1759 (17), 2202 (22), 2532 (28), 1410 (27); cefepime, 0, 64, 130 (23), 0, 0, 0, 802 (20), 1245
(14), 1869 (20), 2396 (28), 1279 (25); imipenem, 35 (8), 161 (16), 264 (23), 0, 477 (13), 755 (17), 1634 (23), 1707 (16), 2176 (22), 2647 (31), 1400 (27); amikacin, 0, 355 (16), 667 (23), 815
(12), 871 (17), 1116 (20), 1648 (25), 1760 (17), 2201 (22), 2605 (28), 1376 (26); ciprofloxacin, 238 (14), 348 (16), 662 (23), 823 (12), 868 (17), 1112 (19), 1645 (26), 1759 (17), 2201 (22),
2671 (28), 1407 (27); and MDR, 0, 0, 0, 866 (13), 860 (17), 1026 (19), 1414 (25), 1759 (18), 2099 (21), 2296 (27), 1370 (27).
The proportions of isolates with full or intermediate resistance to the antibiotics tested for 1–3 years only were, respectively: amoxycillin–clavulanate, 1998, 98 (227 isolates, 23
hospitals); piperacillin, 1997, 98 (127 isolates), 1998, 98 (218 isolates, 23 hospitals); ticarcillin–clavulanate, 1997, 95 (132 isolates), 1998, 95 (216 isolates, 23 hospitals); cephalothin,
1998, 91 (207 isolates, 23 hospitals); ceftriaxone, 1998, 97 (655 isolates, 23 hospitals); aztreonam, 1997, 100 (350 isolates), 1998, 99 (663 isolates, 23 hospitals); gentamicin, 1996, 91
(233 isolates, nine hospitals), 1997, 83 (353 isolates), 1998, 70 (665 isolates, 23 hospitals); tobramycin, 1997, 71 (352 isolates), 1998, 73 (670 isolates, 23 hospitals); netilmicin, 1996,
71 (130 isolates, nine hospitals), 1997, 62 (139 isolates), 1998, 73 (241 isolates, 23 hospitals); co-trimoxazole, 1998, 73 (665 isolates, 23 hospitals); and norfloxacin, 1998, 89 (144
isolates, 23 hospitals).
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empirical treatment of ICU patients with infection
in Greek hospitals, where the great majority of
A. baumannii isolates have the advanced antimi-
crobial resistance pattern revealed by this analysis
[17], at least until the results of cultures and
in-vitro antimicrobial susceptibility tests become
available [18,19]. Measures for the control of
resistance have also been recommended; in par-
ticular, the Greek Center for Disease Prevention
and Control (KEELPNO) has issued guidelines
concerning general measures and infection con-
trol, hand hygiene and antibiotic prescribing
practices.
It should be acknowledged that the present
study has several limitations. First, clinical infor-
mation was not available for the patients from
whose clinical specimens the isolates were
identified. Second, the number of hospitals parti-
cipating in the in-vitro susceptibility study was
not constant during the study period. This fact
causes some problems in the interpretation of the
comparative data regarding the proportion of
A. baumannii isolates that had full or intermediate
resistance and the proportion of A. baumannii
isolates among all clinical isolates from hospital-
ised patients. Third, standard microbiological
methods were used in the participating laborat-
ories for the identification and in-vitro suscepti-
bility testing of A. baumannii isolates; given the
difficulties in the correct identification and
classification of members of the genus Acinetob-
acter, some mistakes are probably unavoidable in
routine clinical microbiology practice. Finally, the
study did not attempt to identify or take account
Table 2. Antimicrobial resistance of Acinetobacter baumannii isolates from patients hospitalised in medical and surgical
wards of Greek hospitals
Proportion of isolates with full or intermediate resistance
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006a
Medical wards
Ampicillin–sulbactam 20 51 49 33 37 34 50 41 47 46 49
Piperacillin–tazobactam 0 ND ND 65 75 66 69 70 80 79 83
Ceftazidime 33 67 75 70 82 73 74 83 85 84 88
Cefepime ND 49 65 66 75 66 74 82 83 78 86
Imipenem 8 10 7 8 3 9 24 36 38 52 71
Amikacin 25 63 64 59 65 54 42 73 76 77 79
Ciprofloxacin 36 56 72 68 82 76 80 82 87 86 90
MDRb ND ND ND ND ND ND 511 63 72 73 75
Surgical wards
Ampicillin–sulbactam 25 43 41 25 27 40 47 50 51 48 51
Piperacillin–tazobactam 100 ND ND 72 87 72 67 80 84 85 87
Ceftazidime 75 82 85 83 81 83 79 87 89 91 92
Cefepime ND 63 61 76 73 77 78 86 87 85 90
Imipenem 5 5 5 4 18 17 19 43 41 56 71
Amikacin 70 71 69 72 79 68 62 77 80 81 86
Ciprofloxacin 43 65 76 73 78 81 83 90 91 94 93
MDRb ND ND ND ND ND ND 63 68 75 78 82
aData available for the second semester of 2002 for MDR, and the first semester of 2006.
bMDR, multidrug-resistant (resistance to ceftazidime, ciprofloxacin and amikacin).
ND, no data.
For medical wards, the numbers of isolates tested and the maximum number of hospitals that provided data (in parentheses) per year for the 11 consecutive years of the study
(1996–2006) were, respectively: ampicillin–sulbactam, 5 (3), 125 (16), 213 (23), 167 (21), 139 (23), 320 (26), 116 (31), 350 (8), 325 (11), 338 (18), 145 (12); piperacillin–tazobactam, 4
(3), 0, 0, 199 (21), 149 (23), 430 (26), 212 (31), 703 (19), 735 (24), 835 (27), 446 (27); ceftazidime, 6 (3), 152 (16), 238 (23), 239 (21), 160 (23), 487 (26), 272 (31), 721 (21), 782 (28), 916
(33), 484 (30); cefepime, 0, 31, 34 (23), 274 (24), 104 (23), 305 (26), 168 (31), 498 (17), 683 (25), 858 (31), 426 (28); imipenem, 12 (3), 63 (16), 69 (23), 131 (21), 70 (23), 350 (26), 251 (31),
701 (22), 779 (28), 913 (33), 473 (30); amikacin, 12 (3), 160 (16), 251 (23), 247 (21), 160 (23), 486 (26), 271 (31), 722 (21), 778 (26), 856 (33), 478 (29); ciprofloxacin, 11 (3), 160 (16), 237
(23), 241 (21), 156 (23), 483 (26), 269 (31), 720 (21), 783 (28), 924 (33), 483 (30); and MDR, 0, 0, 0, 0, 0, 0, 390 (29), 722 (23), 735 (24), 800 (31), 472 (28).
The proportions of isolates with full and intermediate resistance (R and I) to antibiotics tested for 1–3 years only were: amoxycillin–clavulanate, 1998, 76 and 13 (62 isolates, 23
hospitals); piperacillin, 1997, 72 and 9 (47 isolates), 1998, 69 and 9 (54 isolates, 23 hospitals); ticarcillin–clavulanate, 1997, 77 and 9 (35 isolates), 1998, 67 and 7 (42 isolates, 23
hospitals); cephalothin, 1998, 80 and 4 (50 isolates, 23 hospitals); ceftriaxone, 1998, 78 and 8 (232 isolates, 23 hospitals); aztreonam, 1997, 77 and 9 (159 isolates), 1998, 86 and 8
(234 isolates, 23 hospitals); gentamicin, 1997, 52 and 6 (159 isolates), 1998, 52 and 12 (237 isolates, 23 hospitals); tobramycin, 1997, 46 and 3 (159 isolates), 1998, 48 and 8 (248
isolates, 23 hospitals); netilmicin, 1997, 26 and 13 (61 isolates), 1998, 54 and 8 (48 isolates, 23 hospitals); co-trimoxazole, 1998, 71 and 1 (236 isolates, 23 hospitals); and
norfloxacin, 1998, 71 and 4 (52 isolates, 23 hospitals).
For surgical wards, the numbers of isolates tested and the maximum number of hospitals that provided data (in parentheses) per year for the 11 consecutive years of the study
(1996–2006) were, respectively: ampicillin–sulbactam, 4 (4), 178 (16), 339 (23), 138 (19), 124 (23), 301 (29), 122 (37), 240 (7), 231 (10), 290 (17), 134 (11); piperacillin–tazobactam, 3
(4), 0, 0, 162 (19), 153 (23), 440 (29), 190 (37), 518 (18), 614 (23), 775 (27), 357 (23); ceftazidime, 16 (4), 224 (16), 369 (23), 216 (19), 171 (23), 486 (29), 260 (37), 532 (20), 663 (25), 837
(32), 412 (26); cefepime, 0, 67, 55 (23), 147 (19), 109 (23), 331 (29), 179 (37), 393 (17), 569 (23), 775 (30), 375 (24); imipenem, 20 (4), 103 (16), 96 (23), 158 (19), 131 (23), 371 (29), 252
(37), 531 (19), 658 (25), 815 (32), 409 (26); amikacin, 20 (4), 228 (16), 398 (23), 222 (19), 172 (23), 482 (29), 260 (37), 535 (20), 660 (24), 771 (32), 400 (26); ciprofloxacin, 21 (4), 225 (16),
367 (23), 219 (19), 170 (23), 476 (29), 254 (37), 535 (20), 664 (25), 845 (32), 411 (26); and MDR, 0, 0, 0, 0, 0, 0, 300 (27), 531 (21), 608 (23), 718 (30), 400 (26).
The proportions of isolates with full and intermediate resistance (R and I) to antibiotics tested for 1–3 years only were: amoxycillin–clavulanate, 1998, 81 and 11 (85 isolates, 23
hospitals); piperacillin, 1997, 79 and 4 (75 isolates), 1998, 80 and 6 (84 isolates, 23 hospitals); ticarcillin, 1997, 75 and 0 (four isolates); ticarcillin–clavulanate, 1997, 51 and 19 (65
isolates), 1998, 68 and 15 (72 isolates, 23 hospitals); cephalothin, 1998, 78 and 0 (76 isolates, 23 hospitals); ceftriaxone, 1998, 87 and 5 (362 isolates, 23 hospitals); aztreonam, 1997,
86 and 9 (219 isolates), 1998, 90 and 5 (366 isolates, 23 hospitals); gentamicin, 1997, 63 and 13 (226 isolates), 1998, 54 and 21 (370 isolates, 23 hospitals); tobramycin, 1997, 67 and
2 (220 isolates), 1998, 66 and 5 (393 isolates, 23 hospitals); netilmicin, 1997, 56 and 1 (89 isolates), 1998, 56 and 6 (89 isolates, 23 hospitals); co-trimoxazole, 1998, 72 and 1 (366
isolates, 23 hospitals); and norfloxacin, 1998, 74 and 2 (50 isolates, 23 hospitals).
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of any possible clonal spread of resistant organ-
isms. Thus, major outbreaks caused by epidemic
clonal spread of a single resistant strain would be
reflected by an apparent major increase in anti-
microbial resistance levels, but this might reflect
particular local circumstances that resulted in an
outbreak rather than an overall increase in resist-
ance among Acinetobacter clinical isolates in
general. Nevertheless, the data add information
concerning the high proportions of resistance
among A. baumannii clinical isolates from hospi-
talised patients, as has also been reported from
several other regions of the world [20–22]. Con-
tinuous surveillance of the in-vitro antimicrobial
susceptibility of A. baumannii isolates in various
geographical areas is necessary in order to gen-
erate data useful for optimising empirical antimi-
crobial treatment of patients with infections that
are likely to be caused by this pathogen.
ACKNOWLEDGEMENTS
The Greek System for the Surveillance of Antibiotic Resistance
is sponsored by KEELPNO (Ministry of Health and Social
Solidarity of Greece).
REFERENCES
1. Naas T, Coignard B, Carbonne A et al. VEB-1 extended-
spectrum beta-lactamase-producing Acinetobacter bau-
mannii, France. Emerg Infect Dis 2006; 12: 1214–1222.
2. Alp E, Esel D, Yildiz O, Voss A, Melchers W, Doganay M.
Genotypic analysis of Acinetobacter bloodstream infection
isolates in a Turkish university hospital. Scand J Infect Dis
2006; 38: 335–340.
3. Wu CJ, Lee HC, Lee NY et al. Predominance of Gram-
negative bacilli and increasing antimicrobial resistance in
nosocomial bloodstream infections at a university hospital
in southern Taiwan, 1996–2003. J Microbiol Immunol Infect
2006; 39: 135–143.
4. Amazian K, Fendri C, Missoum MF et al. Multicenter pilot
survey of resistant bacteria in the Mediterranean area. Eur
J Clin Microbiol Infect Dis 2006; 25: 340–343.
5. Prashanth K, Badrinath S. Nosocomial infections due to
Acinetobacter species: clinical findings, risk and prognostic
factors. Ind J Med Microbiol 2006; 24: 39–44.
6. Ling TK, Ying CM, Lee CC, Liu ZK. Comparison of anti-
microbial resistance of Acinetobacter baumannii clinical
isolates from Shanghai and Hong Kong. Med Princ Pract
2005; 14: 338–341.
7. Falagas ME, Karveli EA. The changing global epidemiol-
ogy of Acinetobacter baumannii infections: a development
with major public health implications. Clin Microbiol Infect
2007; 13: 117–119.
8. Clinical and Laboratory Standards Institute. Performance
standards for antimicrobial susceptibility testing, 16th infor-
mational supplement, M100-S16. Wayne, PA: CLSI, 2006.
9. Giakkoupi P, Petrikkos G, Tzouvelekis LS et al. Spread of
integron-associated VIM-type metallo-beta-lactamase
genes among imipenem-nonsusceptible Pseudomonas
aeruginosa strains in Greek hospitals. J Clin Microbiol 2003;
41: 822–825.
10. Giakkoupi P, Xanthaki A, Kanelopoulou M et al. VIM-1
metallo-beta-lactamase-producing Klebsiella pneumoniae
strains in Greek hospitals. J Clin Microbiol 2003; 41:
3893–3896.
11. Tsakris A, Ikonomidis A, Pournaras S et al. VIM-1 metallo-
beta-lactamase in Acinetobacter baumannii. Emerg Infect Dis
2006; 12: 981–983.
12. Pournaras S, Markogiannakis A, Ikonomidis A et al. Out-
break of multiple clones of imipenem-resistant Acinetob-
acter baumannii isolates expressing OXA-58 carbapenemase
in an intensive care unit. J Antimicrob Chemother 2006; 57:
557–561.
13. Kraniotaki E, Manganelli R, Platsouka E, Grossato A,
Paniara O, Palu G. Molecular investigation of an outbreak
of multidrug-resistant Acinetobacter baumannii, with char-
acterisation of class 1 integrons. Int J Antimicrob Agents
2006; 28: 193–199.
14. Rice LB. Challenges in identifying new antimicrobial
agents effective for treating infections with Acinetobacter
baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2006;
43 (suppl): S100–S105.
15. Townsend ML, Pound MW, Drew RH. Tigecycline: a new
glycylcycline antimicrobial. Int J Clin Pract 2006; 60: 1662–
1672.
16. Rose WE, Rybak MJ. Tigecycline: first of a new class of
antimicrobial agents. Pharmacotherapy 2006; 26: 1099–1110.
17. Falagas ME, Kasiakou SK, Nikita D, Morfou P, Georgou-
lias G, Rafailidis PI. Secular trends of antimicrobial
resistance of blood isolates in a newly founded Greek
hospital. BMC Infect Dis 2006; 6: 99.
18. Falagas ME, Rafailidis PI. When to include polymyxins in
the empirical antibiotic regimen of critically ill patients
with fever? A decision analysis approach. Shock (in press).
19. Falagas ME, Kasiakou SK. Colistin: the revival of poly-
myxins for the management of multidrug-resistant
gram-negative bacterial infections. Clin Infect Dis 2005; 40:
1333–1341.
20. Ishii Y, Alba J, Kimura S, Yamaguchi K. Evaluation of
antimicrobial activity of beta-lactam antibiotics by Etest
against clinical isolates from 100 medical centers in Japan
(2004). Diagn Microbiol Infect Dis 2006; 55: 143–148.
21. Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Clonal
occurrences of multidrug-resistant Gram-negative bacilli:
report from the Meropenem Yearly Susceptibility Test
Information Collection Surveillance Program in the United
States (2004). Diagn Microbiol Infect Dis 2006; 54: 249–257.
22. Hujer KM, Hujer AM, Hulten EA et al. Analysis of anti-
biotic resistance genes in multidrug-resistant Acinetobacter
sp. isolates from military and civilian patients treated at
the Walter Reed Army Medical Center. Antimicrob Agents
Chemother 2006; 50: 4114–4123.
Research Notes 819
 2007 European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 816–842
